In a recent evaluation of Hamlet Pharma, the European Commission concluded that Hamlet
Pharma’s bladder cancer project has delivered exceptional results with immediate or potential
impact. The company was commended by the European Commission for the progress made
during the receipt of the EU Horizon 2020 grant in the EIC Accelerator program. The European
Commission concluded that the project has fully achieved its objectives and milestones for
the period.
After this positive report, the Commission will now transfer to Hamlet Pharma a sum of about
300 000 EUR to be used for the bladder cancer project. This final payment to Hamlet Pharma
will be made during 2023. In total, Hamlet Pharma will have received 2.2 Million EUROS as
part of the EIC Accelerator program of the European Commission.
This payment from the European Commission illustrates the competitiveness of Hamlet
Pharma on the international stage and the good will created by our achievements and hard
work.
For more information, contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46-709 42 65 49,
Catharina.svanborg@med.lu.se
Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77,
martin.erixon@hamletpharma.com
Website: www.hamletpharma.com
About HAMLET Pharma AB
Hamlet Pharma, whose shares are listed on the Spotlight Stock Market, is a company
engaged in drug development based on a tumor-killing protein-lipid complex, HAMLET,
formed from two natural and harmless molecules found in breast milk. The development
aims to produce preparations that are primarily to be used for the treatment and prevention
of cancer diseases. Alpha1H is the synthetic variant of HAMLET, which enabled the
development of the substance for clinical trials. Hamlet Pharma is conducting clinical
development work with Alpha1H in patients with bladder cancer, a difficult to cure and costly
form of cancer. The company is also developing Alpha1H for the treatment of brain tumors
and is currently conducting a Technical Evaluation of BAMLET and intends, if the evaluation
turns out positive, to create conditions suitable for the continued development of BAMLET.
